塞德斯医疗 CLDX 深 沪
已收盘 08-21 16:00:00 美东时间
40.38
+0.440
+1.10%
华盛通- 最 高41.2399
- 今 开40.38
- 成交量 83.77万股
- 最 低 40.12
- 昨 收 39.94
- 总市值 31.71亿
- 52周最高 45.14
- 市盈率 静 --
- 换手率 1.07%
- 52周最低 21.77
- 委 比 68.04%
- 总股本 7852.95万
- 历史最高 582.60
- 量 比 0.86
- 振 幅 2.80%
- 历史最低 1.50
- 每 手 1
- 风险率 5.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $53.
08-07 18:50
财报速睇 | 塞德斯医疗 2026财年Q2营收0.00亿美元，同比下降97.0%；归母净利润亏损0.74亿美元，同比亏损扩大29.9%
华盛资讯8月7日讯，塞德斯医疗公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比下降97.0%，归母净利润亏损0.74亿美元，同比亏损扩大29.9%。
08-07 11:49
财报速睇 | 塞德斯医疗 2026财年Q2营收0.00亿美元，同比下降97.0%；归母净利润亏损0.74亿美元，同比亏损扩大29.9%
华盛资讯8月7日讯，塞德斯医疗公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比下降97.0%，归母净利润亏损0.74亿美元，同比亏损扩大29.9%。
08-07 08:14
Celldex Therapeutics Q2 EPS $(0.94) Beats $(1.07) Estimate, Sales $22.000K Miss $954.444K Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.15 percent. This is a 10.59 percent decrease over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $22.000 t...
08-07 05:57
美股大行评级 | 最高1400美元！花旗、大小摩8家大行上调希捷科技目标价；大行集中调整目标价：康宁、科斯塔、思佳讯遭下调，PayPal、Visa、可口可乐、赛莱默获上调
今日重点评级关注：古根海姆：维持ProMIS Neurosciences"买入"评级，目标价从35美元升至69美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从38美元升至39美元
07-30 11:45
Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72
Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $72.
07-30 00:11
美股大行评级 | 富国银行上调闪迪目标价从1250美元升至1620美元；最高132美元！高盛、大小摩等多家机构上调通用汽车目标价
今日重点评级关注：HC Wainwright & Co.：维持IREN"买入"评级，目标价从85美元升至90美元；BTIG：维持FTAI Aviation"买入"评级，目标价从340美元升至400美元
07-23 13:42
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study
Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday said it is ending its Phase 2 clinical trial evaluating barzolvolimab for prurigo nodularis, a chronic condition characterized by intensely itchy skin nodules. The discontinuation comes after the study failed to achieve its primary and key secondary...
07-22 19:29
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Celldex reported that its Phase 2 study of barzolvolimab in prurigo nodularis (PN) did not meet primary or key secondary endpoints, though the drug showed a favorable safety profile and significant mast cell depletion. Despite profound tryptase reduction, no improvement in symptoms was observed. Barzolvolimab continues to show promise in other indications like chronic spontaneous urticaria and cold urticaria, with Phase 3 data expected in late 20...
07-21 20:01
